Mhanna Amal, Franklin Wayne H, Mancini Anthony J
Department of Pediatrics, Northwestern University's Feinberg School of Medicine, Chicago, Illinois, USA.
Pediatr Dermatol. 2011 Jan-Feb;28(1):39-45. doi: 10.1111/j.1525-1470.2010.01355.x. Epub 2011 Jan 25.
Hepatic infantile hemangiomas may be associated with morbidity and mortality, and traditional therapies may be associated with significant side effects. Since propranolol has been recently used successfully to treat cutaneous infantile hemangiomas, we decided to use it in three patients who presented with hepatic and skin hemangiomatosis. Three patients with skin and hepatic infantile hemangiomas, two of whom had evidence of cardiovascular compromise and one of whom had extensive liver involvement and hypothyroidism, were treated with oral propranolol. Regression of both skin and hepatic hemangiomas was noted in all patients, as was resolution of the cardiac symptoms and decreased thyroid requirement in two patients each. Propranolol was well tolerated without any adverse effects. Propranolol should be considered as a potential first-line therapy in patients with symptomatic hepatic hemangiomatosis.
肝内婴儿血管瘤可能与发病和死亡相关，传统疗法可能伴有显著副作用。由于普萘洛尔最近已成功用于治疗皮肤婴儿血管瘤，我们决定将其用于3例患有肝和皮肤血管瘤病的患者。3例患有皮肤和肝内婴儿血管瘤的患者，其中2例有心血管功能受损的证据，1例有广泛肝脏受累及甲状腺功能减退，接受了口服普萘洛尔治疗。所有患者的皮肤和肝内血管瘤均有消退，2例患者的心脏症状得到缓解，2例患者的甲状腺激素需求减少。普萘洛尔耐受性良好，无任何不良反应。对于有症状的肝血管瘤病患者，应考虑将普萘洛尔作为一种潜在的一线治疗方法。
